A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.
Identifieur interne : 000D12 ( Istex/Curation ); précédent : 000D11; suivant : 000D13A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.
Auteurs : J L Montastruc [France] ; O. Rascol [France] ; A. Rascol [France]Source :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 1989-06.
Abstract
The long term effects of a de novo treatment with levodopa versus bromocriptine were compared in respectively 13 and 15 previously untreated patients with Parkinson's disease in a prospective randomised trial. Thirteen patients were treated with levodopa alone (mean dose 444, SEM 63 mg daily) whereas 15 others received bromocriptine alone (mean dose 50, SEM 6 mg daily) during 37, SEM 4 and 32, SEM 4 months respectively. For a similar decrease in the Columbia rating scale, the nature of long term side effects was different in the two groups: three patients on levodopa developed peak-dose dyskinesias and one other dystonia. With bromocriptine, one patient developed a severe psychosis whereas 3 others suffered from primary lack of efficacy (1 case) or late decrease in efficacy (2 cases). These results demonstrate the potential of D2 dopamine agonists (like bromocriptine) in the de novo treatment of Parkinson's disease; however, their use is limited by their lack of efficacy and/or the occurrence of neuropsychiatric side effects.
Url:
DOI: 10.1136/jnnp.52.6.773
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D14
Links to Exploration step
ISTEX:9D51D464435AA9100CB179B085471D04BA808404Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.</title><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse, France.</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse, France.</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse, France.</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9D51D464435AA9100CB179B085471D04BA808404</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1136/jnnp.52.6.773</idno><idno type="url">https://api.istex.fr/document/9D51D464435AA9100CB179B085471D04BA808404/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D14</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D14</idno><idno type="wicri:Area/Istex/Curation">000D12</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.</title><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse, France.</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse, France.</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse, France.</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology INSERM U317, University Hospital, School of Medicine, Toulouse</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="1989-06">1989-06</date><biblScope unit="volume">52</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="773">773</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">9D51D464435AA9100CB179B085471D04BA808404</idno><idno type="DOI">10.1136/jnnp.52.6.773</idno><idno type="href">jnnp-52-773.pdf</idno><idno type="PMID">2664089</idno><idno type="local">jnnp;52/6/773</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The long term effects of a de novo treatment with levodopa versus bromocriptine were compared in respectively 13 and 15 previously untreated patients with Parkinson's disease in a prospective randomised trial. Thirteen patients were treated with levodopa alone (mean dose 444, SEM 63 mg daily) whereas 15 others received bromocriptine alone (mean dose 50, SEM 6 mg daily) during 37, SEM 4 and 32, SEM 4 months respectively. For a similar decrease in the Columbia rating scale, the nature of long term side effects was different in the two groups: three patients on levodopa developed peak-dose dyskinesias and one other dystonia. With bromocriptine, one patient developed a severe psychosis whereas 3 others suffered from primary lack of efficacy (1 case) or late decrease in efficacy (2 cases). These results demonstrate the potential of D2 dopamine agonists (like bromocriptine) in the de novo treatment of Parkinson's disease; however, their use is limited by their lack of efficacy and/or the occurrence of neuropsychiatric side effects.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D12 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000D12 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:9D51D464435AA9100CB179B085471D04BA808404
|texte= A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.
}}
| This area was generated with Dilib version V0.6.29. |  |